Rubella virus vaccine

DB10317ApprovedInvestigationalVaccinesLive Attenuated Rubella Virus Vaccine

Rubella virus vaccine is a vaccine used to prevent Rubella. It is prepared from RA 27/3 strain of live attenuated rubella virus.

Primary indication
Rubella virus vaccine is used to prevent rubella in combination with other virus vaccines, such as the mumps and measles virus vaccine.Curator reviewed · 5 structured indications
First approval
Canada, 2000 · United States, 1971 · European Union, 2021
Also known as
Rubella virus (vaccine strain RA27/3) live antigen · Rubella virus live antigen, A · Rubella virus strain Wistar RA 27/3 live (attenuated) antigen · Rubella virus strain Wistar RA 27/3 live antigen · Rubella virus vaccine live (Wistar RA 27-3 strain)
Brand names
  • M-M-R II
  • M-M-RVaxPro
  • Proquad

Resolves to

Compound
UNII52202H034Z
Clinical / RWD
RxNorm9486ATCJ07BD51ATCJ07BD52ATCJ07BD53

What you can answer from here — as of May 03, 2025

435Drug interactionsStructured to mechanism, not free text
Sign in
134Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
138Marketed productsAcross 9 countries and 19 labellers
Sign in
6ATC codesIncluding every combination product, plus 8 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Rubella virus vaccine, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In